{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"237.0","value":"463989.35"},{"groupId":"OG001","spread":"90.4","value":"1498869.21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in DNA extracted from PBMC.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794.","id":"OG000","title":"GSK3377794"},{"description":"Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108.","id":"OG001","title":"GSK3377794+Pembrolizumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Modified ITT Population","reportingStatus":"POSTED","timeFrame":"Up to Day 28","title":"Area Under the Plasma Concentration-time Curve From Zero to Day 28 (AUC[0-28])","type":"SECONDARY","unitOfMeasure":"Days*Copies per microgram genomic DNA"}